Unified Patent Court (UPC)


The Unified Patent Court (UPC) has transformed European patent litigation, creating a central forum for patent enforcement and validity challenges across participating EU Member States. As UPC case law continues to develop, businesses and practitioners closely monitor decisions that shape litigation strategy, procedural practice, and the interpretation of substantive patent law.

This category tracks key UPC developments, including infringement actions, revocation proceedings, preliminary injunctions, procedural rulings, and judgments from both the Court of First Instance and the Court of Appeal. Our contributors analyse significant decisions and emerging trends, highlighting their practical implications for patent owners, challengers, in-house counsel, and litigation teams.

For professionals involved in European patent disputes, portfolio management, or freedom-to-operate assessments, this section provides timely commentary and expert analysis of the latest UPC decisions and the evolving body of UPC case law.


546 articles available

The price of proofA confidentiality club is often discussed as though it were an access list. It is a judicial allocation of commercial risk. Most parties still treat it as the last item to settle,…

COMVIK and G 1/19 “technical character” as a shared filter, and what happens when inventive step is not assessed using the EPO’s problem–solution approach.Europe has long grappled with the exclusions…

From remedy to orderFew disputes over UPC injunctions still turn on whether they will issue. The argument has moved to the terms of the order.The Court of Appeal has narrowed the first question with…

The Munich Local Division has now given the UPC’s first ruling applying the “lay open books” procedure under Rule 141 of the UPC Rules of Procedure (r. 141). For parties litigating in the UPC, this…

In Sanofi and Regeneron v. Amgen, the Düsseldorf Local Division upheld a second medical use patent but dismissed the infringement action. The difficulty was proving that the medicine would be…

A failed FRAND negotiation does not end when the parties leave the room. By then they have exchanged claim charts, discussed comparable licenses and moved some distance from their opening positions…

The 2026 AIPPI World Congress, held in Hamburg from 7 to 10 October, brought together IP practitioners, judges, industry representatives and academics from around the world. Its patent programme…

A second medical use patent is often seen as an easy target. The Milan section of the UPC Central Division has just shown that it is much harder to hit when the challenger is required to say exactly…

Remember the caps? In March 2021 this blog asked what it is with the Dutch and money, and reported that the Dutch patent courts had put indication tariffs on recoverable legal costs. Simple case,…